A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies.
In this first retrospective longitudinal study of anti-topoisomerase I autoantibodies (anti-topo I) we examined the isotypic expression in 13 patients with scleroderma by enzyme-linked immunosorbent assay. Titers were stable for up to 16 years. However, one patient lost the antibody, while another developed high levels of IgM with myositis and another, high levels of IgA with cardiac disease. For the first time the de novo development of anti-topo I was observed.
Hildebrandt
S
S
Abteilung für Rheumatologie und Klinische Immunologie, Medizinische Universitätsklinik, Freiburg, Germany.
Jäckh
G
G
Weber
S
S
Peter
H H
HH
D000328:Adult; D001323:Autoantibodies / Q000032:analysis* / Q000276:immunology; D004264:DNA Topoisomerases, Type I / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012595:Scleroderma, Systemic / Q000453:epidemiology / Q000276:immunology; D013997:Time Factors
D001323:Autoantibodies; D007075:Immunoglobulin M; D004264:DNA Topoisomerases, Type I